Analysis of amniotic fluid, maternal plasma, and cord blood for a human breast gross cystic disease fluid protein.
Amniotic fluid was analyzed for the presence of the 15,000 monomer molecular size glycoprotein found in human breast gross cystic disease fluid (GCDFP-15). From 24 weeks' gestation a log-linear increase in levels of GCDFP-15 was noted. The levels of GCDFP-15 doubled every 16 to 28 days, and the highest value recorded was 7,200 ng/ml. At delivery, levels of GCDFP-15 in cord blood plasma were in a background range (mean, 8 ng/ml). Maternal plasma levels of GCDFP-15 were one to tenfold higher in the third trimester of pregnancy when compared to those in nonpregnant women. Since saliva is known to contain high concentrations of GCDFP-15 (10 to 70 micrograms/ml), it is proposed that the levels in amniotic fluid originate from saliva and tracheobronchial secretions.
D000653:Amniotic Fluid / Q000032:analysis*; D001053:Apolipoproteins; D053399:Apolipoproteins D; D001826:Body Fluids / Q000032:analysis; D002352:Carrier Proteins; D005260:Female; D005312:Fetal Blood / Q000032:analysis*; D005348:Fibrocystic Breast Disease / Q000032:analysis; D006023:Glycoproteins / Q000032:analysis* / Q000097:blood; D006801:Humans; D026901:Membrane Transport Proteins; D011247:Pregnancy; D011254:Pregnancy in Diabetics / Q000175:diagnosis
C024328:APOD protein, human; D001053:Apolipoproteins; D053399:Apolipoproteins D; D002352:Carrier Proteins; D006023:Glycoproteins; D026901:Membrane Transport Proteins; C488892:PIP protein, human